生物医药

肿瘤和细菌糖类疫苗、纳米抗体介导的肿瘤免疫治疗和抗体偶联药物

1.Hong, H. F.; Lin, H.; Li, D.; Gong, L.; Zhou, K.; Li, Y.C., Yu, H.Y.; Zhao, K., Shi, J.; Zhou, Z. F.; Huang, Z.H.;Wu, Z. M.,Chemoenzymatic Synthesis of a Rhamnose-Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy. Angew Chem Int Ed 2022, doi.org/10.1002/anie.202208773
2. Zhou, K.; Hong, H. F.; Lin, H.; Gong, L.; Li, D.; Shi, J.; Zhou, Z. F.; Xu, F.; Wu, Z. M., Chemical Synthesis of Antibody-Hapten Conjugates Capable of Recruiting the Endogenous Antibody to Magnify the Fc Effector Immunity of Antibody for Cancer Immunotherapy. J Med Chem 2022, 65 323-332.
3. Lu, Z. K.; Liu, Z. C.; Li, X.; Qin, X. F.; Hong, H. F.; Zhou, Z. F.; Pieters, R. J.; Shi, J.; Wu, Z. M., Nanobody-Based Bispecific Neutralizer for Shiga Toxin-Producing E. coli. Acs Infect Dis 2022, 8 321-329.
4. Li, Y. C.; Gong, L.; Hong, H. F.; Lin, H.; Li, D.; Shi, J.; Zhou, Z. F.; Wu, Z. M., beta-Galactosidase-dependent metabolic glycoengineering of tumor cells for imaging and immunotherapy. Chem Commun 2022, 58 2568-2571.
5. Liu, J. L.; Hong, H. F.; Shi, J.; Xie, Y. T.; Lu, Z. K.; Liu, Z. C.; Zhou, Z. F.; Bian, Z. H.; Huang, Z. H.; Wu, Z. M., Dinitrophenol-mediated modulation of an anti-PD-L1 VHH for Fc-dependent effector functions and prolonged serum half-life. Eur J Pharm Sci 2021, 165.
6. Lin, H.; Zhou, K.; Li, D.; Hong, H. F.; Xie, Y. T.; Gong, L.; Shen, Y.; Zhou, Z. F.; Shi, J.; Wu, Z. M., Dinitrophenol-Hyaluronan Conjugates as Multivalent Antibody-Recruiting Glycopolymers for Targeted Cancer Immunotherapy. ChemMedchem 2021, 16 2960-2968.（封面文章）
7. Hong, H. F.; Li, C.; Gong, L.; Wang, J. F.; Li, D.; Shi, J.; Zhou, Z. F.; Huang, Z. H.; Wu, Z. M., Universal endogenous antibody recruiting nanobodies capable of triggering immune effectors for targeted cancer immunotherapy. Chem Sci 2021, 12 4623-4630.
8. Gong, L.; Li, Y. C.; Cui, K. S.; Chen, Y.; Hong, H. F.; Li, J. M.; Li, D.; Yin, Y.; Wu, Z. M.; Huang, Z. H., Nanobody-Engineered Natural Killer Cell Conjugates for Solid Tumor Adoptive Immunotherapy. Small 2021, 17. （封面文章）
9. Dai, S. J.; Hong, H. F.; Zhou, K.; Zhao, K.; Xie, Y. T.; Li, C.; Shi, J.; Zhou, Z. F.; Nie, L.; Wu, Z. M., Exendin 4-Hapten Conjugate Capable of Binding with Endogenous Antibodies for Peptide Half-life Extension and Exerting Long-Acting Hypoglycemic Activity. J Med Chem 2021, 64 4947-4959.
10. Lin, H.; Hong, H. F.; Wang, J. F.; Li, C.; Zhou, Z. F.; Wu, Z. M., Rhamnose modified bovine serum albumin as a carrier protein promotes the immune response against sTn antigen. Chem Commun 2020, 56 13959-13962. （封面文章）
11. Dai, S.; Liu, S.; Li, C.; Zhou, Z.; Wu, Z. M., Site-selective modification of exendin 4 with variable molecular weight dextrans by oxime-ligation chemistry for improving type 2 diabetic treatment. Carbohydrate Polymers 2020, 249.
12. Hong, H. F.; Zhou, Z. F.; Zhou, K.; Liu, S. Z.; Guo, Z. W.; Wu, Z. M., Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies. Chem Sci 2019, 10 9331-9338.

申请中国专利28项；授权中国专利10项；申请PCT2项；美国专利2项

1: 国家自然科学面上基金 纳米抗体-鼠李糖簇状缀合物的化学酶法合成、抗肿瘤活性及其作用机制（22177040，2022.1-2025.12）
2: 江苏省重点研发计划（社会发展）（ BE2019632 ）
3: 无锡市转化医学专项
4：国家自然科学面上基金 糖基化复杂壁磷壁酸的全合成及其免疫活性研究（21472070，2015.1-2018.12）
5：江苏省特聘教授 糖类药物化学（2015.1-2017.12）
6：江苏省“双创计划” 创新团队（2015.1-2017.12）
7：江苏省“六大人才高峰”项目
8：北京大学天然药物及仿生药物国家重点实验室开放课题

技术咨询